Semaglutide in pill form: the UK's first oral weight-loss GLP-1

You heard about the tablet and wanted to know if it's real

It is. The news travelled fast when the MHRA approved Wegovy tablets in June 2026, understandably so, because the idea of swapping a weekly injection for a daily tablet is genuinely significant for a lot of people. If you found this page because you're needle-averse, or because you've been curious about the oral form of semaglutide since you first heard it existed, that's a completely reasonable place to start.

Wegovy tablets contain semaglutide co-formulated with SNAC, an absorption enhancer that allows the medicine to pass from the stomach into the bloodstream. Without it, semaglutide would be broken down by digestive enzymes before it could act. The combination means you get the same active ingredient as the injection, delivered through a tablet taken first thing in the morning. The MHRA's approval announcements for both forms of Wegovy confirm the active molecule is identical (semaglutide) just administered differently.

The practical routine matters here. You take one tablet in the morning on an empty stomach, with a small amount of plain water, then wait at least 30 minutes before eating, drinking anything else (including coffee), or taking other oral medicines. That window is necessary for proper absorption. Swallow it whole. No fridge needed, room-temperature storage makes it far easier to manage when you're away from home. For anyone who has ever packed ice packs to keep a medicine cool on a flight, that distinction is meaningful.

How the pill form of semaglutide is dosed, and how it differs from the diabetes version

This is a point worth getting right, because confusion between the two oral semaglutide products circulates widely. The Wegovy tablet schedule for weight management runs: 1.5 mg, then 4 mg, then 9 mg, reaching a maintenance dose of 25 mg, with at least one month spent at each level before your prescriber moves you up. The titration is slow by design; the gradual increase helps your body adjust and keeps gastrointestinal side effects manageable.

Rybelsus is also an oral semaglutide tablet, but it is licensed for type 2 diabetes at doses of 3 mg, 7 mg and 14 mg. Those dose levels belong to a completely different licensed indication and a different product. If you've seen mention of a 3 mg or 7 mg semaglutide tablet online in the context of weight loss, it refers to Rybelsus used off-label, not to Wegovy tablets, and our semaglutide pill page explains the distinction between these products in full. The semaglutide tablet form licensed specifically for weight management is Wegovy, full stop.

People already established on the 2.4 mg weekly injection may be able to transfer directly to the 25 mg tablet dose, subject to their prescriber's assessment. That transition is a clinical decision, not a straightforward swap, dosing history, how well the injection has been tolerated, and individual circumstances all factor in.

What the trial evidence actually showed

The phase 3 trial for Wegovy tablets, known as OASIS 4, followed 307 adults with obesity or overweight plus at least one weight-related condition over 64 weeks, comparing the tablet against a placebo alongside lifestyle changes. The headline result: participants using semaglutide in pill form lost an average of around 13.6% of their body weight, compared with roughly 2.4% in the placebo group. Among those who stayed fully adherent to treatment throughout, the average reached approximately 16.6%. That fully-adherent figure is worth stating carefully, it describes a specific subset of participants, not the overall trial population.

The most common side effects in the trial were gastrointestinal: nausea, diarrhoea and vomiting appeared in around 74% of the treatment group, compared with 42% in the placebo group. Most were mild to moderate and tended to settle as the body adjusted, particularly during the early weeks and after each dose increase. The NHS medicines page for semaglutide sets out the broader side-effect picture across both forms of the medicine and is worth reading carefully before starting. If you experience severe, persistent stomach pain that spreads to your back, get medical help promptly, this is listed as an urgent warning sign on the patient information leaflet.

For context on how these results compare with the injection and with tirzepatide, the comparison of oral and injectable semaglutide formats covers the evidence in more detail. Cost context is available on the Wegovy tablet pricing page if that's your next question.

Who the tablet is licensed for, and how clinical assessment works

The MHRA licence covers adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. BMI thresholds under UK guidance may be 2.5 kg/m² lower for some ethnic backgrounds. Meeting those numbers is a starting point, not a guarantee of approval, a prescriber assesses the full clinical picture, including your medical history, other medicines you take, and any contraindications.

The pill form of semaglutide is not recommended during pregnancy, while breastfeeding, or if you are trying to conceive. It is not licensed for use in people under 18. If you are currently on oral contraceptives, discuss this with your prescriber before starting, as with other GLP-1 medicines, the timing of tablet absorption can affect other medicines taken by mouth.

Wegovy tablets are not available on the NHS at present; a NICE appraisal would need to be completed first. Private prescription is the current route. At nume, every consultation is reviewed by a GPhC-registered prescriber on the same day, a real clinician reads your answers, not an automated system. If you'd like to explore whether the tablet is suitable for your situation, the free consultation is the right starting point. Check your eligibility and let the clinical team take it from there.